SkinHealth Systems Bets on Rental and Adjacent Growth Despite Persistent Top-Line Pressure
A Quarter of Two Halves: Revenue Miss, Margin Beat
SkinHealth Systems' second-quarter results neatly captured the tension in its turnaround. Revenue of $72.1 million came in at the low end of guidance, with device sales down 18.4% and Consumables off 3.5% despite a 3.8% increase in the active installed base. Yet adjusted EBITDA of $17 million blew past the $11–13 million guide, driven by a 590 basis point gross-margin improvement to 71.8% and disciplined cost management. As CEO Pedro Malha put it, “Overall, this was a mixed quarter. Revenue came in at approximately $72 million at a lower end of our guidance range. Equipment sales remain the biggest headwind…” — Pedro Malha, CEO · 2026-08-06
The margin strength is not a one-off. Management reiterated that the first-half adjusted gross margin of 72% steps down to the high-60s in the back half as equipment mix and rental-program costs bite, but the earnings power is clearly improving. CFO Mike Monahan noted, “The forecast, the midpoint of our forecast is assumes that we will end the year roughly with about $100 million in cash...” — Michael Monahan, CFO · 2026-08-06 That cash buffer is critical as the company faces a $103 million convertible maturity in October 2026 and a proposed reverse stock split to restore NASDAQ listing compliance.
Strategic Reset: Rental Program and Adjacent Categories
The most significant development is the new rental program launched in early August. It directly attacks the capital-constraint problem that has plagued device placement for over a year. Pedro explained, “we are giving qualified US providers another way to access HydraFacial through a much more manageable payment structure.” — Pedro Malha, CEO · 2026-08-06 The program is a pivot from the traditional ownership model and is designed to expand the installed base without cannibalizing sales—an optimistic but testable claim.
Equally important is the push into adjacent categorys. The company received FDA clearance for periorbital wrinkles on its microneedling device, relaunched Keravive under the HydraScalp banner, and is on track to introduce a brand-new device in the United States in 2027. Pedro described the strategy:
The keyword trajectory highlights these as fresh priorities—recurring revenue and core HydraFacial franchise are central to the narrative, but the rental program is the breakout theme, ranking #1 in the quarter’s keyword list.We are strengthening our commercial capabilities, improving how we engage with customers and becoming more effective at converting opportunities.
Financial Resilience and the Road Ahead
The margin performance validates the cost-control work. The 71.8% adjusted gross margin is a record for the company, but management guided to a step-down in H2 as equipment% rises. Revenue guidance was trimmed to $280–290 million, while adjusted EBITDA guidance was raised to $39–46 million—a rare combination that underscores the profitability transformation. The company’s balance sheet remains stretched, with liabilities-to-assets at 88.3%, but cash generation is improving. The cash position of $26 million is thin relative to the looming convertible, yet management is confident in covering it from operations and cash on hand.
The strategic pivot also echoes prior commentary: in Q1, Pedro already flagged the financing barrier, “we identified pretty clearly that the ability to finance or the ability to qualify for financing continues to be 1 of the major barriers.” — Pedro Malha, CEO · 2026-05-08 The rental program is the tangible answer. Earlier, Mike had noted the gross-margin tailwinds were partly seasonal—“we projected each quarter expected scrap and write-offs, and it was much, much lower than normal in Q1.” — Pedro Malha, CEO · 2026-05-08 That dynamic persisted into Q2, but the company is now signaling it as a structural improvement rather than a one-off.
The market, however, remains skeptical. The stock has fallen ~94% from its 2021 peak, and the recent 90-day trend shows a 25% decline into the print. The clinical outcomes story is intact, but execution risk looms. The rental program’s success hinges on whether it truly expands the provider base without cannibalizing sales. The 2027 device launch is promising but still two years out. For now, the company is buying time with discipline, and if consumables stabilize and the rental program gains traction, the setup for 2027 could be meaningfully better.